Cyclin-dependent kinase 5 is predominantly expressed in postmitotic neurons and plays a role in neurite elongation during development. It has also been postulated to play a role in apoptosis in a variety of cells, including neurons, but little is known about the generality and functional signi®cance of cdk5 expression in neuronal apoptosis in living brain. We have therefore examined its expression and that of its known activators, p35, p39 and p67, in models of induced apoptosis in neurons of the substantia nigra. We ®nd that cdk5 is expressed in apoptotic pro®les following intrastriatal injection of 6-hydroxydopamine and axotomy. It is expressed exclusively in pro®les which are in late morphologic stages of apoptosis. In these late stages, derivation of the pro®les from neurons, and localization of expression to the nucleus, can be demonstrated by co-labeling with a neuron-speci®c nuclear marker, NeuN. In another model of induced apoptotic death in nigra, produced by developmental striatal lesion, kinase activity increases in parallel with cell death. While mRNAs for all three cdk5 activators are expressed in nigra during development, only p35 protein is expressed in apoptotic pro®les. We conclude that cdk5/p35 expression is a general feature of apoptotic neuron death in substantia nigra neurons in vivo.
Cyclin-dependent kinase 5 (cdk5) is a serine/threonine protein kinase which is structurally related to other cdks known for their role in regulating the cell cycle (Lew et al. 1992; Meyerson et al. 1992; . Unlike these other kinases, however, cdk5, which is predominantly expressed in neurons (Meyerson et al. 1992) , is most highly expressed after mitosis is complete (Tsai et al. 1993 ). In addition, unlike other cdks, cdk5 is not dependent on association with cyclins for activation; instead, it is activated by a brain-speci®c protein, p35 (Lew et al. 1994; Tsai et al. 1994) . Two other activators of cdk5, p39 (Tang et al. 1995) and p67 (Shetty et al. 1995) [Munc-18 (Hata et al. 1993) , n-Sec 1 (Pevsner et al. 1994) ] have been identi®ed. It has been suggested that cdk5 and p35 play a role in neural differentiation, because targeted disruption of the genes results in abnormal development (Ohshima et al. 1996; Chae et al. 1997) . At a cellular level, cdk5 and p35 have been identi®ed in axonal growth cones, and suppression of them interferes with normal neurite outgrowth (Nikolic et al. 1996; Paglini et al. 1998 ).
In addition to this role in neural development, cdk5 has been implicated in apoptosis. It is expressed in atretic follicles in the ovary undergoing apoptotic death (Zhang et al. 1997) , and both cdk5 and p35 have been identi®ed in embryonic interdigital tissues undergoing apoptosis . In brain, we observed high levels of cdk5 expression in apoptotic pro®les in natural developmental cell death and in a model of programmed cell death in the substantia nigra (SN) (Henchcliffe and Burke 1997) , induced by developmental lesion to the target striatum (Macaya et al. 1994) . More recently, Patrick and colleagues have shown that coexpression of cdk5 and an N-terminal truncated fragment of p35, p25, induces phosphorylation of neuro®lament and tau, cytoskeletal disruption, and apoptosis in primary cortical neurons in culture (Patrick et al. 1999) . There is much evidence that cdk5 may serve as a kinase for both neuro®laments (Lew et al. 1992; Hisanaga et al. 1993; Shetty et al. 1993; Guidato et al. 1996; Sun et al. 1996; Pant et al. 1997; Qi et al. 1998 ) and tau (Baumann et al. 1993; Paudel et al. 1993; Hosoi et al. 1995) , and it may play an important role in the generation of the hyperphosphorylated tau epitopes identi®ed in neuro®brillary tangles characteristic of Alzheimer's disease (Imahori and Uchida 1997 ). Patrick and others demonstrated p25 in neurons containing neuro®brillary tangles in Alzheimer brain (Patrick et al. 1999) and others have demonstrated cdk5 (Pei et al. 1998) . cdk5 and p35 have also been identi®ed in Lewy bodies of Parkinson's disease (Brion and Couck 1995; Nakamura et al. 1997a Nakamura et al. , 1997b , which contain phosphorylated neuro®laments. Thus, there is growing interest in the role played by cdk5 and p35 in apoptosis, and whether their activity in this role as both neuro®lament and tau kinase may relate to the pathogenesis of neurodegenerative disease.
Very little is known, however, of the role that cdk5 and its activators play in apoptosis in living brain. Our previous observation of cdk5 expression in natural cell death and in one model of induced death in the SN (Henchcliffe and Burke 1997 ) raises several questions. Is cdk5 expression a general feature of apoptosis in SN? Is it, for example, expressed when apoptosis is induced by a neurotoxin or cell injury? To address this question we have examined its expression in such models of induced death, one induced by intrastriatal injection of the neurotoxin 6-hydroxydopamine (6OHDA) (Marti et al. 1997) , and another induced by axotomy of the medial forebrain bundle during development ( Fig. 1 ). In our earlier study, cdk5 expression was observed in simple, rounded apoptotic pro®les which lacked neuronal cytoplasmic features. The following questions arise: Is cdk5 expression observed in apoptotic pro®les which are derived from neurons? Is its expression localized to the nucleus? To address these issues we have performed double-labeling for cdk5 and a speci®c marker of neuronal nuclei, NeuN (Mullen et al. 1992) . There are also questions about the functional signi®cance of cdk5 expression. Is it associated with increased enzyme activity? Is it associated with coexpression of known cdk5 activators and, if so, which ones speci®cally? We address herein these issues in the striatal target injury and 6OHDA models.
Materials and methods

Animal models
Striatal lesions with quinolinic acid Striatal quinolinic acid (QA) lesions were performed as previously described (Macaya et al. 1994; Kelly and Burke 1996) on postnatal day (PND) 7 or PND 12 rats: following induction of anesthesia by hypothermia, a 28 gauge cannula was inserted into the striatum at 3.0 mm left of and 0.5 mm anterior to bregma, at a depth of 4.0 mm. QA (480 nmol/mL) in 0.1 m phosphate-buffered saline (PBS; pH 7.4) was infused by pump at 1.0 mL/2.0 min. The PND 12 animals were used in the immunohistochemical studies, to facilitate tissue processing. We have previously shown that the magnitude, distribution and morphology of cell death in SN is identical between PND 7 and 14 (Kelly and Burke 1996) . This protocol has been approved by The Animal Care and Use Committee at Columbia-Presbyterian Medical Center.
6-Hydroxydopamine lesions 6-Hydroxydopamine (6OHDA) lesions were performed as previously described (Marti et al. 1997) . The PND 7 rat pups were Fig. 1 Models of programmed cell death (PCD) in the substantia nigra (SN). Natural cell death (NCD) occurs in the SN pars compacta (SNpc) and SN pars reticulata (SNpr) of rat, predominantly during the ®rst two postnatal weeks (Janec and Burke 1993; Oo and Burke 1997) . This death event in SNpc can be augmented by axonsparing lesion of the target striatum (STR) with quinolinic acid (QA) (Macaya et al. 1994) , destruction of dopamine neuron terminals with 6OHDA (Marti et al. 1997) , or by axotomy (AXOT).
pretreated with 25 mg/kg desmethylimipramine, anesthetized by hypothermia, and placed prone on an ice pack. The skull was exposed by a midline incision, and a burr hole placed 3.0 mm lateral to the left of bregma on the coronal suture. A 28 gauge cannula was then inserted vertically into the striatum to a depth of 4.0 mm from the top of the skull. 6OHDA hydrobromide (Regis, Marton Grove, IL, USA) was prepared at 15 mg (total weight)/ 1.0 mL in 0.9% NaCl/0.02% ascorbic acid, and infused by pump (Harvard Apparatus, Holliston, MA, USA) at a rate of 0.25 mL/min. The cannula was slowly withdrawn 2 min after the end of the infusion. After recovery from anesthesia, pups were returned to the dams until the assigned post-lesion day.
Medial forebrain bundle axotomy
The PND 7 rat pups were anesthetized by hypothermia. Animals were then positioned in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA, USA) to conform with the neonatal brain atlas described by Heller et al. (1979) . The apparatus is equipped with a hypothermic miniaturized stereotaxic adapter for neonatal rats (Stoelting Co., Wood Dale, IL, USA). The medial forebrain bundle is transected as follows: a retractable wire knife (Kopf Instruments) is lowered through a hole 1.4 mm posterior and 2.5 mm lateral to bregma to a ventral position of 6.5 mm below bregma. The blade is extended by 2 mm, and the knife is slowly moved upward by 2.5 mm, down by same distance, up again, and ®nally down by 2.5 mm.
Tissue processing and immunohistochemistry
Tissue processing
The PND 12 rat pups were anesthetized with halothane vapor, a thoracotomy performed, and the left cardiac ventricle cannulated with a 20G needle. Each animal was then perfused with ice-cold 0.9% NaCl by gravity for 5 min. They were then perfused with ice cold 4% paraformaldehyde/0.1 m phosphate buffer (PB) by gravity for 10 min. This procedure conforms to National Institutes of Health guidelines and has been approved by the Institutional Animal Care and Use Committee of Columbia University. The brain was then carefully removed from the skull and post-®xed in the same ®xative for varying lengths of time at 48C, depending on the primary antibody used. The brain was then cryoprotected in 20% w/w sucrose in 0.1 m PB for 24 h. The brains were then rapidly frozen in 2-methylbutane chilled on dry ice, and sectioned through the entire SN at 20 mm on a cryostat.
Immunoperoxidase staining
For all protocols, sections were collected into PBS and processed free-¯oating. For cdk5 staining, brains were post-®xed for 24 h at 48C. After washes in PBS, sections were pretreated with Trisbuffered saline/0.02% Triton(TBS-T)/2.0% goat serum, and then incubated in primary antibody [Santa Cruz Biotechnology, Santa Cruz, CA, USA; rabbit polyclonal anti-cdk5 (C-8)] at 1 : 500 in this solution for 48 h at 48C. Sections were then treated with biotinylated goat anti-rabbit (Vector Laboratories, Burlingame, CA, USA) at 1 : 100 for 60 min at ambient room temperature. Following additional washes, sections were incubated with avidin±biotin± horseradish peroxide complexes (ABC, Vector Labs) at 1 : 600 for 60 min at room temperature. Following washes in TBS, sections were incubated in a solution of 3,3
H -diaminobenzidine (50 mg in 100 mL Tris buffer at pH 7.6) containing glucose oxidase, ammonium chloride and d(1) glucose to generate H 2 O 2 . Monospeci®city of the C-8 antibody for cdk5 in immature rat SN was con®rmed by western analysis demonstrating a single band at the expected molecular weight (33 kDa) (Fig. 2a) . The validity of the immunostaining of cdk5 was further supported by additional staining experiments with a second primary antibody [Santa Cruz; mouse monoclonal (J-3)], which was also determined by western analysis to be monospeci®c for cdk5 in immature SN (Fig. 2b) .
For p35 staining brains were post-®xed for 3 h at 48C. Sections were treated in 0.1 m PBS (pH 7.1)/0.5% bovine serum albumin (BSA). Sections were then incubated in primary antibody (Santa Cruz; anti-p35 C-19, directed to the C-terminal) at 1 : 25 for 48 h at 48C. Sections were washed and then incubated with biotinylated Protein A, prepared in this laboratory, at 1 : 100 in PBS/BSA for 60 min at room temperature. Following additional washes, sections were incubated with avidin±biotin±horseradish peroxidase complexes (ABC, Vector Labs) at 1 : 600 for 60 min at room temperature. Following washes in PBS, sections were incubated a second time in ABC for 60 min. Following washes in PBS, sections were incubated in a solution of diaminobenzidine (50 mg in 100 mL Tris buffer at pH 7.6) containing glucose oxidase, ammonium chloride and d(1) glucose to generate H 2 O 2 .
Sections for p39 staining were processed like those for p35, except they were incubated in PBS/BSA/0.1% Triton at 48C with shaking for 30 min prior to treatment with primary antibody. Sections were incubated with a monospeci®c antibody to p39 [kindly provided by Dr Alfredo Caceres (Paglini et al. 1998) ] at 1 : 25 for 48 h. Brains for p67 immunostaining were post-®xed for 24 h. Sections for p67 were treated in similar fashion to those for p39, except they were treated with ABC only once. Sections were incubated in a monospeci®c antibody to p67 [kindly provided by Dr Harish Pant ] at 1 : 500 for 48 h.
Brains for SMI 34 staining were post-®xed for 3 h. Sections were incubated in primary antibody (Sternberger-Meyer Inc., Lutherville, MD, USA) at 1 : 1000 in PBS/10% horse serum for 24 h at 48C. After washes, they were treated with biotinylated horse antimouse (Vector Labs) at 1 : 50 for 24 h 48C. They were then treated with ABC and 3,3 H -diaminobenzidine. Sections for AT8 staining were processed in similar fashion using primary antibody (Polymedco, Cortlandt Manor, NY, USA) at 1 : 100 for 24 h.
Immuno¯uorescence double-labeling Brains were post-®xed for 24 h. Sections were cut at 20 mm and then incubated with TBS-T/2% goat serum/2% horse serum. They were then incubated with anti-cdk5 (1 : 500) or anti-NeuN (Chemicon, Temecula, CA, USA; 1 : 100) or both for 48 h at 48C. Following washes, they were incubated with Texas redconjugated horse anti-mouse at 1 : 75 and¯uorescein-conjugated goat anti-rabbit at 1 : 75 in TBS-T/2% goat serum/2% horse serum for 1 h. Sections were then stained with Hoechst 33342 (Molecular Probes, Eugene, OR, USA) at 1 : 500 to visualize apoptotic chromatin clumps. Sections were coverslipped with Dako anti-fade medium and viewed with appropriate ®lters by epi¯uorescence on a Nikon Eclipse 800 microscope. Images were captured with a Spot II digital camera and single channel images were merged using Adobe Photoshop.
Qualitative morphologic analysis
In the immunoperoxidase stained material, apoptosis was identi®ed at the light microscope level by performing a thionin counterstain and visualizing intranuclear chromatin clumps as one or more intensely basophilic, homogeneously stained, round and distinctly bounded structures. We have previously shown for both the striatal lesion and the 6OHDA models that apoptotic pro®les so identi®ed are con®rmed to be apoptotic by electron microscopy [Macaya et al. (1994) and unpublished observations]. Pro®les so identi®ed can also be con®rmed as apoptotic by TUNEL labeling and suppressed silver staining (Macaya et al. 1994; Marti et al. 1997) . In the immuno¯uorescence double-labeled material, apoptotic pro®les were identi®ed by the presence of intensely¯uorescent, round and distinctly bounded structures within the nucleus on UV illumination.
Quantitative morphologic analysis
Apoptotic pro®les in each SN were quanti®ed by selecting two sections from each of Paxinos±Watson (Paxinos and Watson 1982) SN planes 4.2, 3.7 and 3.2 and scanning the entire SN at 600 Â. Apoptotic pro®les were identi®ed as cellular pro®les containing one or more distinct, rounded basophilic chromatin clumps. Free extracellular chromatin clumps, lying outside an identi®able cellular pro®le, were not counted. The number of pro®les in the two sections in a given plane were averaged, to provide a measure for that plane, and then the averages for the three planes were added to provide an index of the number of pro®les for each SN. We have previously shown, using a physical dissector technique (Gundersen 1986) , that apoptotic pro®les, as de®ned, are rarely split by the microtome blade . Clarke and Oppenheim have demonstrated a similar result (Clarke and Oppenheim 1995) . Thus apoptotic pro®les, identi®ed by focusing through the section, represent unique and unbiased counts.
MRNA studies
Molecular probes
To create molecular probes for cdk5, p35, p39 and p67, oligonucleotide primers for the coding region of each were based on published sequence information: cdk5 H (accession number L26087, rat). We generated cDNA from the extracted RNA from SN tissues by reverse transcription using a RETROscript kit (Ambion, Austin, TX, USA). For cdk5, p35 and p67 the PCR products were cloned into a pGEM-T vector (Promega, Madison, WI, USA). For p39 we used the Ambion Lig'nScribe system to incorporate the T7and SP6RNA polymerase promoters into the p39 PCR product. We then used RNA polymerase T7 to synthesize antisense, and SP6to synthesize sense.
Northern analysis
The SN was microdissected at 4, 24 and 48 h after QA injection. Each brain was placed in a rat brain matrix on ice and a 2-mm coronal section of the midbrain was taken. The coronal section was placed posterior surface down on an ice cold glass plate, and the SN was visualized. A horizontal cut was made below the cerebral aqueduct, and the dorsal piece was discarded. The ventral piece was divided mid-sagittally into the left (Experimental) and right (Control) SN, which were then frozen on dry ice and stored at 2 808 until RNA isolation. RNA was isolated from each SN individually using a QIAGEN RNAeasy mini kit (Valencia, CA, USA). Each piece of tissue, weighing approximately 10 mg, was homogenized in 350 mL of buffer provided by passing it through a 22 gauge needle with a 1-mL syringe 10 times. Further steps of the RNA isolation were carried out according to the manufacturer's instructions. RNA concentration was then determined by measuring absorption at 260 nm on a GenQuant spectrophotometer (Pharmacia, Piscataway, NJ, USA). Ten micrograms of each RNA sample per lane were electrophoresed in 1.4% agarose±formaldehyde gels and equal loading of lanes was con®rmed by examination of the gels under UV illumination following ethidium bromide staining. RNA was transferred onto an Immobilon-Ny 1 membrane (Millipore Corporation, Bedford, MA, USA) using a capillary system (Sambrook et al. 1989) overnight in 2 Â SSC. After transferring, RNA was crosslinked to the membrane by UV exposure in a FUNA-UV-Linker (Spectroline, Upland, CA, USA). Hybridization was performed overnight at 678C in ULTRAhyb (Ambion). Washing was carried out according to the manufacturer's recommendations. The membrane was then dried in air, wrapped and exposed to Biomax X-ray ®lm (Kodak).
Ribonuclease protection assay (RPA) Tissues were dissected as described above. Total RNA from the SN was extracted using the ToTALLY RNA extraction kit (Ambion). All probes were labeled with [a-32 P]UTP, using MAXIscript in vitro transcription kit (Ambion). The RPA was performed using RPA II kit from Ambion. The integrated optical density of protected radioactive RNA bands was obtained using the PhosphoImagere 445 SI and the ImageQuante image analysis program (Molecular Dynamics, Sunnyvale, CA, USA) and expressed as phosphorimager counts (PI counts). To subtract background from the phophorimager counts, the local average option of the ImageQuant tm program was used.
In situ hybridization For in situ hybridization, rats were killed at 4 or 24 h after striatal lesion. Rats were perfused intracardially with chilled saline for 5 min, and the brains then rapidly removed and frozen by immersion in 2-methylbutane on dry ice. The brains were then serially sectioned through the SN at 14 mm. Sections were thawmounted onto slides (Superfrost w Plus, VWR), and stored at 2 808C until use. For hybridization, sections were warmed and then ®xed by immersion in 4% paraformaldehyde/0.1 m PB (pH 7.1) for 7 min, rinsed twice in PBS, and delipidated by successive immersion in higher concentrations of ethanol, and then chloroform. Sections were prehybridized at 408C for 2 h with 1 : 1 formamide : prehybridization mix as previously described . Sections were then hybridized with 1 : 1 formamide : hybridization mix at 408C overnight. Labeled riboprobe (prepared as described above) was added to a ®nal activity of approximately 6000 cpm/mL of the 1 : 1 formamide : hybridization solution. Following hybridizations, sections were washed in 2 Â SSC, and then treated with Fig. 3 Immunoperoxidase staining of cdk5 in apoptotic pro®les in SNpc following induction of cell death by intrastriatal injection of 6OHDA or axotomy. In panels (a±e), lesion was performed with by 6OHDA injection and animals were studied on PLD4; in (f ) it was performed by axotomy and the animals were studied at PLD2. A, cdk5 immunoreactivity, indicated by brown reaction product, encompassing three basophilic apoptotic chromatin clumps. (b) A typical, rounded cdk5-positive pro®le, containing two basophilic chromatin clumps, is shown in contrast to an apoptotic pro®le which contains three intranuclear apoptotic chromatin clumps (black arrows) and which retains neuronal cytoplasmic morphology. (c) Many cdk5-positive pro®les were observed in late stages of cellular disintegration, exempli®ed by this pro®le which is breaking down into two smaller, rounded fragments, each containing a chromatin clump. (d) Many cdk5-positive pro®les containing apoptotic chromatin clumps were observed to be adjacent to cdk5-positive cellular fragments which did not contain nuclear chromatin (arrowhead). (e) A cdk5-positive apoptotic body (arrowhead) is observed adjacent to a larger cdk5-positive pro®le. Neither structure contained apoptotic chromatin. (f ) A cdk5-positive apoptotic pro®le is observed in the SNpc of a PND 10 rat at 48 h after axotomy. Bar 10 mm. Fig. 4 Immunostaining of cdk5 and p35 in normal neural tissue. (a) cdk5 immunoreactivity is observed in an axon (arrowheads) in cortex in a PND 12 rat. The surrounding faint peroxidase staining is due to neuropil staining out of the plane of focus. (b) p35 staining in axons (arrowheads) of a fasciculus of cranial nerve III ®bers within the mesencephalon at PND 12. Similar staining was observed in other axon bundles, including the medial longitudinal fasciclus and the corpus callosum (not shown). Neither neuronal cytoplasm nor nuclear staining was observed, the latter exempli®ed by one neuron (white arrow) in this thionin-counterstained section. Bar 10 mm.
RNAase at 378C for 30 min. They were then washed in 2 Â SSC for 60 min at 508C, followed by immersion in 4 L of 0.1 Â SSC/ 0.05% sodium pyrophosphate/14 mm mercaptoethanol at 408C for 3 h with gentle stirring. Sections remained in this wash at room temperature overnight. They were then dehydrated in ethanol/ ammonium acetate, vacuum dried, and apposed to X-ray ®lm at 2 808C for 3±4 weeks. 14 C standards embedded in plastic (Amersham Pharmacia Biotech, Piscataway, NJ, USA) were enclosed in each cassette. Relative optical density measurements for the SNpc were made with a Loats Associates Inquiry image analysis system, as previously described ).
Cdk5 kinase assay SN tissue, dissected as described, was homogenized in 200 mL of ice-cold buffer containing 50 mm Tris HCl pH 7.5; 5 mm EDTA; 10 mm EGTA; 50 mm NaF; 250 mm NaCl; 0.1% Triton X-100; 100 mm sodium vanadate; 50 mg/mL PMSF; 1 mg leupeptin. Lysates were centrifuged and the concentration of protein in the supernatant was assayed (BCA kit, Pierce, Rockford, IL, USA). Two hundred micrograms of protein was used in each kinase assay. The lysate was precleared with 10 mL of Protein A-Sepharose 4B. Anti-cdk5 antibody (Santa Cruz; C-8) was added and incubated 2.0 h at 48C. Thirty microliters of Protein A-Sepharose 4B was added and incubated overnight at 48C. The sepharose beads were pelleted, and then a Histone H1 assay was performed. Thirty microliters of assay buffer (50 mm Tris HCl at pH 7.5, 10 mm MgCl 2 , 20 mm EGTA, 0.1 mm sodium vanadate, 6 mm glycerophosphate, 1.0 mm DTT) containing 10 mm ATP; [g- 
Results
Cdk5 is expressed in apoptotic pro®les in SNpc following intrastriatal 6OHDA injection and axotomy Following 6OHDA lesion, intense peroxidase staining for cdk5 was observed in rounded apoptotic pro®les, as we had previously observed for natural cell death and death induced by early target injury (Henchcliffe and Burke 1997) . This intense peroxidase staining was observed only in rounded pro®les which ranged in size from 3 to 10 mm, and which usually, but not always, contained distinct, round, basophilic apoptotic chromatin clumps (Fig. 3) . The pro®les which did not contain chromatin clumps were typically observed either adjacent to (Fig. 3d) , or budding from (Fig. 3e) other apoptotic pro®les, so we interpret them to be apoptotic bodies. Similar observations were made with the Santa Cruz J-3 monoclonal antibody. As we have previously reported (Henchcliffe and Burke 1997) , a small number of pro®les with identical cellular morphology (data not shown) were observed on the contralateral control side in both models, due to natural cell death during this developmental period (Janec and Burke 1993; Oo and Burke 1997) . Fig. 5 The time course of expression of total apoptotic pro®les, cdk5-positive pro®les with characteristic apoptotic chromatin (cdk51/apo 1), and cdk5-positive pro®les without chromatin clumps (cdk51/apo-) in the SNpc following intrastriatal 6OHDA injection. Basal levels of natural cell death on the non-lesioned control side vary 5-fold during this postnatal period (Janec and Burke 1993) , so for ease of comparison the counts of total and cdk5-positive apoptotic pro®les have been normalized across developmental ages by subtracting values on the contralateral, uninjected control (C) side from values on the ipsilateral experimental (E) side. At each time point, total apoptotic pro®les are represented as mean^stan-dard error of the mean for the difference between sides E and C. An N of 5±6 was analyzed for each time point (for a total of 28 animals). As previously reported (Marti et al. 1997) , induction of apoptotic death is apparent by post-lesion day 4 (PLD), persists to PLD8, and begins to abate by PLD10. The expression of cdk5-positive pro®les, both with and without apoptotic chromatin clumps, follows this time course.
cdk5-positive pro®les were always rounded, resembling nuclei in their size and shape. cdk5 immunoreactivity was never observed in either the nucleus or cytoplasm of apoptotic pro®les which retained a cytoplasmic neuronal morphology (Fig. 3b) . This observation suggests that ckd5 expression is a late event in neuronal apoptosis, occurring after cytoplasmic features have been lost. In support of this possibility, ckdk5 immunoreactivity was often observed in apoptotic pro®les at a point when they were breaking down into smaller cellular fragments (Fig. 3c) .
In contrast to the perinuclear staining demonstrated in Fig. 3 , cdk5 immunostaining in normal neurons was largely con®ned to axons (Fig. 4a) as we and others have reported (Tsai et al. 1993; Henchcliffe and Burke 1997) . Some faint staining of cytoplasm was also observed, but nuclear staining was never observed in normal neurons. Staining was not observed in glia.
In order to further examine the relationship between the presence of the rounded cdk5-positive pro®les which lacked apoptotic chromatin clumps and the cell death process, we examined the time course of their expression in relation to the time course of induced cell death and expression of cdk5-positive pro®les containing apoptotic chromatin clumps (Fig. 5) . The time course of their expression paralleled that of total and cdk5-positive apoptotic pro®les, further supporting the concept that they are derived from apoptotic pro®les. This analysis also revealed that not all apoptotic pro®les within the SNpc following 6OHDA injection are cdk5-positive. At post-lesion day (PLD) 4, the mean total number of apoptotic pro®les in the experimental SN was 12.7, whereas the mean total number of cdk5-positive pro®les with chromatin clumps was 2.8, or 22%. Cdk5 is expressed in NeuN-positive apoptotic pro®les in the striatal target and 6OHDA lesion models While we have interpreted the lack of remaining cytoplasmic neuronal features to mean that cdk5 expression is a late event in neuronal death in these models, an alternative interpretation is that cdk5 may not be expressed in neurons undergoing apoptosis in spite of the fact that it is normally expressed in them (Tsai et al. 1993 ). It would theoretically be possible that it is expressed in a non-neuronal cell population which undergoes apoptosis. To determine whether cdk5 immunoreactivity is expressed in apoptotic pro®les derived from neurons, we have examined the colocalization of cdk5 expression with a speci®c marker for neuronal nuclei, NeuN (Mullen et al. 1992; Wolf et al. 1996) and apoptotic chromatin clumps in the striatal lesion and 6OHDA models. This analysis revealed that cdk5-positive apoptotic pro®les did demonstrate positive NeuN staining in the 6OHDA (Fig. 6 ) and striatal lesion (not shown) models, thus indicating that they were, in fact, derived from neurons. It is notable, however, that NeuN staining of apoptotic pro®les was less intense than that of normal-appearing neurons, suggesting that expression of this antigen diminishes as neurons die. It is therefore possible that other apoptotic pro®les, which were NeuN negative, may have also derived from neurons. The colocalization with NeuN also demonstrates that in dying apoptotic neurons cdk5 expression is in the nucleus, unlike healthy neurons, where the expression is predominantly in the axon (Fig. 4a) .
Cdk5 activity is increased in the SN following induction of apoptosis in the striatal lesion model In order to assess the functional signi®cance of increased numbers of cdk5-immunoreactive pro®les in models of induced programmed cell death in SN, we used a histone 1 phosphorylation assay following speci®c immunoprecipitation of cdk5 from SN tissue extracts at various times following striatal target lesion with QA (Macaya et al. 1994) . This model results in an abrupt and relatively brief induction of cell death, with a peak at 24 h (Macaya et al. 1994) . This analysis revealed that cdk5 activity does increase in SN, at the time of peak induction of cell death at 24 h post-lesion (Fig. 7) .
Cdk5 mRNA levels in SN are unchanged in the striatal target lesion model To explore the molecular basis of increased cdk5 protein expression and activity in the striatal target injury model, we examined cdk5 mRNA expression in SN by northern analysis, ribonuclease protection assay (RPA) and in situ hybridization. Quantitative analysis of SN cdk5 mRNA expression by RPA revealed that there was no increase following striatal lesion at 4, 24 or 48 h (Figs 8a and b) . Other investigators have reported two mRNA transcripts for cdk5 in brain (Ino et al. 1994; Uchida et al. 1994) . We therefore performed northern analysis in order to determine if there were effects on their relative abundance, but no differences were identi®ed (Fig. 8c) . In situ hybridization revealed expression of cdk5 mRNA in SNpc at this developmental age (Fig. 8d) , but there was no increase in the experimental SNpc (not shown). We therefore conclude that increases in cdk5 protein expression are likely to be mediated at a post-transcriptional level.
MRNA for cdk5 activators p35, p39 and p67 is expressed in the developing SN In order to further examine the functional signi®cance and regulation of cdk5 activation with induced death in SN, we determined the relative abundance of mRNAs for its activators p35, p39 and p67 during development, and upon induction of cell death in the target injury model. RPA of RNA derived from SN at PND 7 revealed that a protected band could be identi®ed for each of these activators (Fig. 9a) . mRNA for p39 and p35 was present in about equal abundance, whereas mRNA for p67 was about twice as abundant as either of the other species (Fig. 9b ). An analysis of the expression of these mRNAs by RPA, Northern analysis and in situ hybridization following induction of cell death by striatal injury revealed that their expression was not increased (data for p35 is shown in Fig. 10 ; data for p39 and p67 is not shown).
Protein expression of p35, but not p39 or p67 is associated with apoptosis in the 6OHDA and striatal target lesion models Given the relative abundance of p67 mRNA, we examined by immunohistochemistry its protein expression in both the target injury and 6OHDA models in relation to cell death. Immunostaining clearly revealed positive ®bers within the molecular layer of the immature cerebellum, as previously reported (Fig. 11a) . However, p67 staining was never observed within apoptotic pro®les in the SN in either the target injury or the 6OHDA models (Fig. 11a, inset) . p39 immunostaining was observed in cerebellar Purkinje cells, as reported (Honjyo et al. 1999) ( Fig. 11b) , but, like p67, it was never observed in apoptotic pro®les in the SN in either model of induced cell death (Fig. 11b, inset) .
In normal neural tissue, immunostaining for p35 using an antibody to the C-terminal (Santa Cruz C-19) demonstrated ®ber staining within fasciculated axon bundles, but not in neuronal cytoplasm or nuclei (Fig. 4b) . Clear immunoperoxidase staining was observed in apoptotic pro®les in the SN in both the striatal target lesion model and the 6OHDA model (Figs 11c±f). As was the case for cdk5, p35 staining was observed only in small, rounded apoptotic pro®les; it was never observed in apoptotic pro®les which retained neuronal cytoplasmic features. Like cdk5, p35 staining was not observed in all apoptotic pro®les; in the target model it was observed in 16% of apoptotic pro®les at PLD1; in the 6OHDA model it was observed in 15% of pro®les at PLD6. Attempts to stain p35 using an antibody to the N-terminal (SC-821) were unsuccessful. While this negative result may have a technical explanation, it is also compatible with the possibility that the p25 N-truncated form of p35 is present in apoptotic pro®les in vivo, as reported in tissue culture (Patrick et al. 1999) .
Apoptotic pro®les in SN do not express neuro®lament or tau phosphorylated epitopes recognized by SMI34 or AT8 cdk5 has been proposed to serve as both a neuro®lament (Lew et al. 1992; Sun et al. 1996; Pant et al. 1997) and tau Hosoi et al. 1995; Vincent et al. 1997) kinase in brain, and phosphoepitopes within both neuro®lament and tau have been identi®ed in conjunction with cdk5/p35-associated apoptosis in cortical neurons in culture (Patrick et al. 1999) . To examine this functional aspect of cdk/p35 expression during apoptosis in vivo, we performed immunohistochemistry for these phosphoepitopes using two well-characterized antibodies, SMI34 to phosphoneuro®lament H (Sternberger and Sternberger 1983 ) and AT8 to phosphorylated tau (Mercken et al. 1992) . AT8 intensely stained ®bers and punctate structures within the molecular layer of developing cerebellum (Fig. 12a) , but it did not stain apoptotic pro®les in either the striatal lesion or the 6OHDA lesion models. SMI34 stained axonal ®bers, as anticipated, but it also did not stain apoptotic pro®les in either model (Fig. 12b) . We thus conclude that while SMI34 staining has been observed in neurons (Patrick et al. 1999) , and AT8 staining in both neurons (Patrick et al. 1999) and PC12 cells (Nuydens et al. 1997) undergoing apoptosis in culture, this is not observed in these neurons in vivo.
Discussion
Natural cell death is a general feature of neural development, with up to 50% of neurons dying by apoptosis during critical developmental periods (Oppenheim 1991) . A natural cell death event occurs among neurons of the SNpc in rat (Janec and Burke 1993; Oo and Burke 1997) and mouse (Jackson-Lewis et al. 2000) . It is largely a postnatal event, with an initial major peak on PND 2, and a second minor peak on PND 14. Classic neurotrophic theory (Clarke 1985; Barde 1989) would predict that this death event in SNpc is likely to be dependent on interactions with the striatum, the major target for these neurons, and we have shown that this is likely to be the case, because developmental axon sparing injury to the striatum results in an approximately 10-fold induction of cell death (Macaya et al. 1994) . Since both natural cell death and induced death in SNpc following striatal lesion are regulated by target interactions, it is likely that they share similar death mechanisms. We have shown that these death events have a similar time course (Kelly and Burke 1996) and identical apoptotic morphology both by standard histology (Macaya et al. 1994) and by immunohistochemistry for the activated form of caspase-3 (Jeon et al. 1999) . It is therefore not surprising that cdk5 expression, ®rst identi®ed in the striatal lesion model, is also observed, with identical cellular morphology, in natural cell death in SNpc (Henchcliffe and Burke 1997) , and following axotomy (Fig. 3f) , which, like target injury, disrupts neurotrophic support.
While induced death in SNpc following intrastriatal injection of 6OHDA may also be mediated in part by disruption of target interactions due to destruction of terminals, it also appears to be mediated by a direct effect of the toxin as well. Unlike the striatal lesion model, the 6OHDA model of programmed cell death can be induced, albeit at lower levels, at postnatal ages later than 2 weeks, and in young adult animals (Marti et al. 1997) . In addition, the cellular pattern of activated caspase-3 expression differs in the 6OHDA model from what is observed in natural cell death and the striatal lesion model; it is observed extensively within the cytoplasm, rather than just in the nucleus (Jeon et al. 1999) . Thus, our observation that cdk5 is expressed in apoptotic pro®les in this model, mediated by a neurotoxin, suggests that cdk5 expression is likely to be a general feature of apoptosis in SNpc neurons.
However, we found in this model, as we did in the natural cell death, axotomy and striatal lesion models, that cdk5 expression was never observed in pro®les which retained neuronal cytoplasmic features. It was therefore not possible, on the basis of a thionin counterstain, to determine whether these positive pro®les were, in fact, derived from neurons. To address this issue we performed double labeling for cdk5 and NeuN, a speci®c marker for nuclei derived from neurons (Mullen et al. 1992; Wolf et al. 1996) . We have con®rmed that these two proteins can be colocalized in apoptotic pro®les, thus demonstrating that some are derived from neurons in both the striatal target lesion and the 6OHDA models. The number of pro®les demonstrating colocalization of cdk5 and NeuN is likely to be an underestimate of the number actually derived from neurons, because the intensity of NeuN staining was clearly less in pro®les undergoing apoptosis in comparison to adjacent, healthy neurons. Given that some of the apoptotic pro®les in the 6OHDA model are derived from neurons, it is likely that some are derived from dopaminergic neurons, because 6OHDA is a catecholamine neuron-selective neurotoxin and apoptotic death has been identi®ed in phenotypically de®ned dopamine neurons in this model (Marti et al. 1997 ). Our conclusion that cdk5 is expressed in neurons undergoing apoptosis is compatible with the known cellular expression of the protein within neurons (Tsai et al. 1993) .
The demonstration of colocalization of cdk5 expression with NeuN also indicates that as neurons undergo apoptosis, the expression of cdk5 changes from being predominantly axonal in the healthy neuron to being exclusively nuclear.
We have therefore observed cdk5 expression in neurons of the SNpc in four different paradigms of programmed death, which are likely to be mediated by at least two different mechanisms, target interaction-and toxin-related. In addition, we have previously observed cdk5 expression in cortex and the mamillary body in circumstances of natural and induced death, respectively (Henchcliffe and Burke 1997) . We therefore conclude that cdk5 expression is likely to be a general feature of apoptotic neuronal death, and is thus likely to serve as a useful marker for such.
In our previous studies of apoptotic neuronal death in the striatal lesion and 6OHDA models we have observed a spectrum of morphology among apoptotic pro®les ranging from fairly intact-appearing neuronal pro®les to small, rounded pro®les which appear to be only nuclear remnants (Macaya et al. 1994; Marti et al. 1997) . Among the intact neuronal pro®les we have been able to identify expression of tyrosine hydroxylase, a cytoplasmic marker of dopamine neurons (Macaya et al. 1994; Marti et al. 1997) , and c-jun, which is expressed early in the course of cell death . While in the striatal lesion model activated caspase-3 expression is observed exclusively in small, round nuclear remnants, in the 6OHDA model it is observed throughout the cytoplasm in neurons which morphologically look intact (Jeon et al. 1999) . However, in both of these models we have observed cdk5 staining exclusively in small, round pro®les without cytoplasmic features. We interpret this observation to mean that cdk5 expression is a late event in the death of these neurons. In support of this interpretation, we frequently observed cdk5 expression in apoptotic pro®les undergoing cellular breakdown (e.g. Fig. 3c ) and in adjacent apoptotic bodies (Figs 3d and e) .
The appearance of cdk5 protein in late apoptotic pro®les could represent a functionally signi®cant cellular response, or, alternatively, it could represent a passive and nonfunctional re-distribution of protein from axons, where it is known to be expressed (Tsai et al. 1993) , to the cell soma. To address this issue in part, we examined cdk5 kinase activity during the course of induced death in the striatal lesion model, and found that it increases in parallel. Thus the cdk5 protein expression observed by immunohistochemistry in this model is associated with functionally active enzyme. We doubt that the cdk5 expression observed by immunostaining is due simply to passive re-distribution for several additional reasons: (i) it is not distributed throughout the soma, but rather is intimately associated with nuclear NeuN staining; (ii) it is associated with a similar distribution of p35 staining; and (iii) other known axonal proteins, including p67, tau and neuro®lament, do not show this pattern of staining.
Of the three known neuronal protein activators of cdk5, p35, p67 and p39, only p35 was found to be expressed in apoptotic pro®les in our models, suggesting that it is a speci®c activator of cdk5 in apoptosis. p35 is N-terminally truncated to form p25, a regulatory subunit which is the predominant form of the protein in brain extracts and which more highly activates cdk5 (Lew et al. 1994; Lee et al. 1996) . Patrick and colleagues have shown that coexpression of p25, but not p35, with cdk5 in cortical neurons results in cytoskeletal disruption and apoptosis (Patrick et al. 1999) . In our studies, the use of an antibody directed toward the C-terminal does not permit us to distinguish between the p35 and p25 forms. In addition, the magnitude of cell death at any given time in these models is not enough to attempt a demonstration of the p25 form at a tissue level by western analysis. Exploration of the form of p35 in neuronal apoptosis in vivo will require future investigation at a cellular level with speci®c antibodies.
Using a variety of techniques we were unable to demonstrate an increase in mRNA for either cdk5 or p35 in SN in the striatal lesion model of induced death. This result would suggest that the increases in cdk5 and p35 protein expression were not mediated by increased mRNA transcription. A similar result for cdk5 and p35 was reported by Ahuja and coworkers .
The results reported here demonstrate a correlation between cell death and expression of both cdk5 and p35 in these models, but they do not provide direct evidence that these molecules mediate cell death. The investigations of Patrick and colleagues, demonstrating that increased expression of cdk5 and p25 induce apoptosis in primary cortical neurons in vitro would suggest, however, that they may be mediators. One important difference, however, between our in vivo results, and those of Patrick and colleagues is that we do not observe expression of phosphorylated neuro®lament and tau epitopes, in spite of clear staining for these epitopes in normal nerve ®bers. In addition, at the time we observed cdk5 and p35 staining, there were only nuclear remnants and no remaining cytoplasmic elements. Thus, in these in vivo models of apoptosis in SN we do not detect evidence that cdk5/p35 phosphorylates cytoskeletal elements as a prelude to their disruption and apoptotic death.
